SILVER SPRING, MD, December 22, 2014 (GLOBE NEWSWIRE) – Nuvilex, Inc. (OTCQB: NVLX), a clinical-stage biotechnology company providing cell therapy solutions for the treatment of diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Nuvilex orphan drug designation for its pancreatic cancer treatment. Nuvilex’s pancreatic cancer treatment combines Nuvilex’s patented and
Read more →SILVER SPRING, Md., Dec. 18, 2014 (GLOBE NEWSWIRE) — Nuvilex, Inc. (NVLX), a clinical-stage biotechnology company providing cell and gene therapy solutions for the treatment of diseases, today announced that its partner, Austrianova, successfully completed the first live cell encapsulation at Austrianova’s new facility in the Thai Science Park in Bangkok, Thailand. This is an
Read more →SILVER SPRING, MD, December 16, 2014 (GLOBE NEWSWIRE) – Nuvilex, Inc. (OTCQB: NVLX), a clinical-stage biotechnology company providing cell solutions for the treatment of diseases, today announced a shareholder update on the Company’s cancer and diabetes programs utilizing its Cell-in-a-Box® cellulose-based live cell encapsulation technology. The first preclinical study by TD2 in the U.S. that
Read more →SILVER SPRING, Md., Dec. 10, 2014 (GLOBE NEWSWIRE) — Nuvilex, Inc. (NVLX), a clinical-stage biotechnology company providing cell therapy solutions for the treatment of diseases, is pleased to provide an update on the significance of its partner, Austrianova, opening a new, state-of-the-art current Good Manufacturing Practices (cGMP)-compliant live-cell encapsulation facility inside the Thailand Science Park
Read more →Pancreatic cancer is a “medical emergency” and must be treated as such if the situation for patients is to be improved, says J-Matthias Löhr. As professor of gastroenterology and hepatology at Sweden’s Karolinska Institutet, Löhr has direct experience in tackling what has been referred to as the world’s ‘greatest oncological challenge’. “This is a threefold
Read more →SILVER SPRING, MD., Dec. 8, 2014 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB: NVLX), a preclinical and clinical-stage biotechnology company providing cell therapy solutions for the treatment of diseases, announced today that it has changed the name of its subsidiary, Medical Marijuana Sciences, Inc., to Viridis Biotech, Inc. This name change is part of PharmaCyte
Read more →SILVER SPRING, MD, December 4, 2014 (GLOBE NEWSWIRE) – PharmaCyte Biotech, Inc. (OTCQB: NVLX), a clinical-stage biotechnology company providing cell therapy solutions for the treatment of diseases, announced today that PharmaCyte Biotech executives joined Thailand government officials at the grand opening of Austrianova’s current Good Manufacturing Practices (cGMP) live-cell encapsulation facility within the Thai Science
Read more →SILVER SPRING, MD, December 1, 2014 (GLOBE NEWSWIRE) – PharmaCyte Biotech, Inc. (OTCQB: NVLX), a clinical-stage biotechnology company developing cell therapy solutions for the treatment of diseases, announced today that it has obtained an exclusive worldwide license from Austrianova Singapore Pte Ltd to use the unique and proprietary Cell-in-a-Box® cellulose-based live cell encapsulation technology in
Read more →SILVER SPRING, Md., Nov. 24, 2014 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (NVLX), a clinical-stage biotechnology company providing cell therapy solutions for the treatment of diseases, announced today that it has formed a “Diabetes Consortium” that will be tasked with the development of PharmaCyte Biotech’s treatment for insulin-dependent diabetes. The composition of the Diabetes Consortium
Read more →SILVER SPRING, MD, November 21, 2014 (GLOBE NEWSWIRE) – PharmaCyte Biotech, Inc. (OTCQB: NVLX), a clinical-stage biotechnology company providing cell therapy solutions for the treatment of diseases, announced today PharmaCyte Biotech’s Chief Executive Officer, Kenneth L. Waggoner, and Chief Operating Officer, Gerald W. Crabtree, Ph.D., are in Singapore to finalize the Diabetes Consortium that will
Read more →